Research Desk Line-up: 22nd Century Post Earnings Coverage

LONDON, UK / ACCESSWIRE / August 28, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Kamada Ltd (NASDAQ: KMDA), following which we have published a free report that can be viewed by signing up at http://protraderdaily.com/optin/?symbol=KMDA. Kedrion Biopharma and Kamada announced on August 25, 2017, that the US Food and Drug Administration (FDA) has approved KEDRAB?, a human rabies immune globulin (HRIG), for the post-exposure prevention of rabies infection, when administered after contact with a rabid or possibly rabid animal. The FDA approved KEDRAB? based on positive data from the Phase-2/3 Clinical trials conducted on 118 healthy subjects in the US. The drug is expected to be launched in US in early Q1 2018. For immediate access to our complimentary reports, including today's coverage, register for free now at:

http://protraderdaily.com/register/

Discover more of our free reports coverage from other companies within the Biotechnology industry. Pro-TD has currently selected 22nd Century Group, Inc. (NYSE American: XXII) for due-diligence and potential coverage as the Company announced on August 09, 2017, its financial results for Q2 2017. Tune in to our site to register for a free membership, and be among the early birds that get our report on 22nd Century when we publish it.

At Pro-TD, we make it our mission to bring you news that matter about the stock you follow. Today, our research desk covers a blog story on KMDA; also brushing on XXII. Go directly to your stock of interest and access today's free coverage at:

http://protraderdaily.com/optin/?symbol=KMDA

http://protraderdaily.com/optin/?symbol=XXII

Commenting on receiving approval for KEDRAB?, Paolo Marcucci, President and CEO of Kedrion said:

"The approval of KEDRAB represents the first product that Kedrion Biopharma has had a role in developing throughout its clinical development and through to commercialization in the US. Rabies is a deadly, but entirely preventable disease, and we are pleased to offer physicians another safe and effective option."

Amir London, CEO of Kamada added:

"We are proud that our unique and advanced immune globulin purification technology was used in the development of KEDRAB, and look forward to a successful launch of the product with Kedrion Biopharma. The BLA approval may also serve as basis for registration in other countries. This treatment represents an annual market opportunity of over $100 million in the US, of which we expect to take a significant market share."

About KEDRAB? and its Market Potential

KEDRAB? is a plasma-derived human rabies immune globulin (HRIG). It is a protein therapeutic derived from hyper-immune plasma, which is plasma that contains high levels of antibodies from donors that have been previously exposed to rabies. It is a prophylactic treatment against rabies infection that is administered to patients after exposure to an animal suspected of being infected with rabies. KEDRAB? is to be administered concurrently along with the full course of rabies vaccine. It is administered via a one-time injection in a precise dosage based on a patient's weight.

Kamada's HRIG drug - KamRAB is marketed in over 10 countries worldwide since 2006 and has already sold more than 1.4 million vials till date. Kamada and Kedrion S.p.A entered into a strategic agreement in December 2015 for the clinical development and marketing of KamRAB as KEDRAB? in US, subject to receiving approval from FDA. Kamada holds the license for KEDRAB?, and Kedrion Biopharma has exclusive rights to commercialize the product in the US. KEDRAB? represents a market opportunity of $100 million-plus on a yearly basis in US.

Kamada expects that the FDA approval for KEDRAB? will allow it to capture a major share in the $100 million annual market pie and improve its profit margins from the US markets. The Company plans to leverage the FDA approval to expand its global market share for KEDRAB?.

On the other hand, the FDA approval of KEDRAB? will enable Kedrion to expand its current portfolio of immune globulin products which includes RhoGAM® and GAMMAKED?. The Company is an enviable position and is well-equipped to maximize the potential of this product and launch KEDRAB? in the US.

Before the FDA's approval for KEDRAB?, healthcare professionals in the US has only two other HRIG options to choose from when treating patients who may have been exposed to rabies and to prevent its onset. The two HRIG options are Imogam produced by Sanofi Pasteur and HyperRAB produced by Grifols. The availability of both these HRIG options has been impeded by inconsistent supply in recent years.

About Rabies

Rabies is a preventable deadly virus that spreads to people from the saliva of infected animals via bites and scratches. According to the WHO (World Health Organization), in 99% of all rabies transmissions to humans, dogs are the main source of human rabies deaths. Post-exposure prophylaxis (PEP) is the immediate treatment of a bite victim after rabies exposure. This prevents virus entry into the central nervous system, which results in imminent death. Rabies impact's approximately 40,000 people in US annually.

About Kamada Ltd

Kamada was founded in 1990 and is headquartered in Nes Ziona, Israel. It is a biopharmaceutical Company that is focused on plasma-derived protein therapeutics for orphan indications. The Company uses its proprietary technology for the extraction and purification of proteins from human plasma to produce Alpha-1 Antitrypsin (AAT) in a highly-purified, liquid form, as well as other plasma-derived proteins. AAT is a protein derived from human plasma with known and newly-discovered therapeutic roles given its immunomodulatory, anti-inflammatory, tissue-protective and antimicrobial properties. Kamada's Glassia® is the first and only liquid, ready-to-use, intravenous plasma-derived AAT product approved by US FDA. Kamada markets Glassia® in US via its strategic partner Baxalta. The Company also has a portfolio of several other pharmaceutical products that are marketed in over 15 countries, including Israel, Russia, Brazil, India, and other countries in Latin America and Asia, through distributors.

About Kedrion Biopharma

Kedrion Biopharma Inc. is the US based subsidiary of Italy's Kedrion SpA and it is headquartered in Fort Lee, New Jersey. The Company started its US operations in 2011 and is engaged in the production of blood and plasma-derived products. Kedrion Biopharma has expanded its operations and it is present in markets of over 100 countries in Asia, Europe, and North and South America. The Company has also acquired rights to collect, produce, and market significant products for treating or preventing hemophilia and Rh sensitization which can lead to hemolytic disease of the new-born.

Last Close Stock Review

At the closing bell, on Friday, August 25, 2017, Kamada's stock climbed 5.81%, ending the trading session at $4.55. A total volume of 1.78 million shares have exchanged hands, which was higher than the 3-month average volume of 141.61 thousand shares. The Company's stock price advanced 0.44% in the previous twelve months. The stock currently has a market cap of $170.17 million.

Pro-Trader Daily:

Pro-Trader Daily (Pro-TD) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. PRO-TD has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles, and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

PRO-TD has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email contact@protraderdaily.com. Rohit Tuli, a CFA® charter holder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by PRO-TD. PRO-TD is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

PRO-TD, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. PRO-TD, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, PRO-TD, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither PRO-TD nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://protraderdaily.com/disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: contact@protraderdaily.com

Phone number: (917) 341.4653

Office Address: Mainzer Landstrasse 50 Frankfurt am Main, Germany 60325

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Pro-Trader Daily